Amicus Therapeutics, Inc. stock is down -1.59% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52.94% of the previous 16 December’s closed higher than November. In the last 4 Unusual Options Trades, there were 2 CALLs, 2 PUTs. 0% of analysts rate it a buy.
Amicus Therapeutics, Inc. focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases.